Provention Bio to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM EST. The event will be webcast live, accessible through the company's website, and archived for 30 days. Provention focuses on developing therapies for immune-mediated diseases, with a pipeline targeting conditions like Type 1 Diabetes, celiac disease, and lupus. For additional information, visit www.ProventionBio.com.

RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15^th, 2023 at 11:20am EST.

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation. 

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a commercial-stage biopharmaceutical company focused on advancing the development and commercialization of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Kristen Kelleher, Senior Manager, Investor Relations
investorrelations@proventionbio.com

Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-svb-securities-global-biopharma-conference-301740966.html

SOURCE Provention Bio, Inc.

FAQ

When is Provention Bio's presentation at the SVB Securities Global Biopharma Conference?

Provention Bio will present on February 15, 2023, at 11:20 AM EST.

How can I access the Provention Bio conference presentation?

The presentation will be webcast live on Provention Bio's website and archived for 30 days.

What does Provention Bio specialize in?

Provention Bio specializes in the development of therapies for immune-mediated diseases, including Type 1 Diabetes and lupus.

Where can I find more information about Provention Bio?

More information about Provention Bio can be found at their official website, www.ProventionBio.com.

What is the stock symbol for Provention Bio?

The stock symbol for Provention Bio is PRVB.